PPARG and type 2 diabetes mellitus: The effects of tesaglitazar on augmenting insulin mediated control of hepatic and skeletal muscle glucose metabolism are consistent with the results of a number of studies with other PPARγ agonists on glucose metabolism in both animal models [31] and even patients with type 2 diabetes [32].